The Discounted Cash Flow (DCF) valuation of Navidea Biopharmaceuticals Inc (NAVB) is (378.65) USD. With the latest stock price at 0.08 USD, the upside of Navidea Biopharmaceuticals Inc based on DCF is -486171.7%.
Based on the latest price of 0.08 USD and our DCF valuation, Navidea Biopharmaceuticals Inc (NAVB) is a sell. selling NAVB stocks now will result in a potential gain of 486171.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
Range | Selected | |
WACC / Discount Rate | 5.7% - 8.1% | 6.9% |
Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
Fair Price | (1,506.28) - (222.21) | (378.65) |
Upside | -1933709.2% - -285348.4% | -486171.7% |